Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27732247 | 0.82 | PIK3CG (0.51) | PIK3CGMAPTLMNACYP1A2THRB | |
| SCHEMBL610347 | 0.80 | POLB (0.46) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10896219 | 0.80 | STS (0.37) | PIK3CGKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL14508206 | 0.76 | ELANE (0.39) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL516693 | 0.75 | MAPT (0.58) | MAPTLMNACYP1A2KMT2AALDH1A1 | |
| SCHEMBL15355870 | 0.73 | S1PR3 (0.44) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL9896463 | 0.73 | PIK3CG (1.00) | PIK3CGMAPTLMNACYP1A2THRB | |
| SCHEMBL10950114 | 0.72 | PIK3CG (0.66) | PIK3CGMAPTLMNACYP1A2THRB | |
| SCHEMBL4390043 | 0.72 | PIK3CG (0.66) | PIK3CGMAPTLMNACYP1A2THRB | |
| SCHEMBL4474238 | 0.72 | PIK3CA (0.52) | MAPTLMNAMTORAKT1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436040-B2 | Method of treating conditions involving PPAR-receptors with indole compounds | LABORATOIRES FOURNIER S.A. (FR) | 2013-05-07 | — | — | US | disclosed |
| CN-101242833-B | Pyrrolopyridine derivatives and use of same as PPAR receptor modulators | FOURNIER LAB SA | 2012-06-27 | — | — | CN | disclosed |
| US-7863306-B2 | Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD (IE) | 2011-01-04 | — | — | US | disclosed |
| US-7863306-B2 | Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD (IE) | 2011-01-04 | — | — | US | disclosed |
| US-7863306-B2 | Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD (IE) | 2011-01-04 | — | — | US | disclosed |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | LABORATORIES FOURNIER S.A. (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7795297-B2 | Indole compounds, method of preparing them and uses thereof | LABORATORIES FOURNIER S.A. (FR) | 2010-09-14 | — | — | US | disclosed |
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20100029632-A1 | BROADSPECTRUM 2-AMINO-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SURLERAUX DOMINIQUE LOUIS NEST | 2010-02-04 | — | — | US | disclosed |
| US-20100029632-A1 | BROADSPECTRUM 2-AMINO-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SURLERAUX DOMINIQUE LOUIS NEST | 2010-02-04 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| CN-1636006-A | Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors | TIBOTEC PHARM LTD (IE) | 2005-07-06 | — | — | CN | disclosed |
| US-20040132791-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-07-08 | — | — | US | disclosed |
| CN-1507446-A | Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors | ̩���ؿ�ҩƷ����˾ | 2004-06-23 | — | — | CN | disclosed |
| US-20040106661-A1 | especially for multi-drug resistant strains | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-06-03 | — | — | US | disclosed |
| EP-1397367-A2 | BROADSPECTRUM 2-(SUBSTITUTED-AMINO)-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1387842-A1 | BROADSPECTRUM 2-AMINO-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092595-A1 | BROADSPECTRUM 2-AMINO-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002081478-A2 | BROADSPECTRUM 2-(SUBSTITUTED-AMINO)-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106661-A1 | especially for multi-drug resistant strains | CYP2S1, CBR1, CYP8B1 | PIK3CG 1676/4885MAPT 4807/4885LMNA 2024/4885 |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | GPR119, PPARA, PPARG | PIK3CG 1110/4885MAPT 730/4885LMNA 1980/4885 |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | NR0B1, NR0B2, NR2C2 | PIK3CG 3072/4885MAPT 4879/4885LMNA 2725/4885 |
| US-20040132791-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | ALOX15B, CYP2B6, ALOX12 | PIK3CG 3240/4885MAPT 4871/4885LMNA 2180/4885 |
| US-20100029632-A1 | BROADSPECTRUM 2-AMINO-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | CYP2S1, CYP2C8, CYP2A7 | PIK3CG 3704/4885MAPT 4791/4885LMNA 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.